Discover the Latest Breakthrough in Mental Health Treatment: Teva’s SOLARIS Trial Reveals Promising Results for Once-Monthly Subcutaneous Injection TEV-749 Olanzapine
Teva Pharmaceuticals Announces Positive Results for SOLARIS Trial New Hope for Patients with Schizophrenia In a groundbreaking announcement, Teva Pharmaceuticals revealed new positive efficacy, safety, and tolerability results for the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial, evaluating TEV-‘749 in adult patients diagnosed with schizophrenia. The study showed that TEV-‘749 met the primary…